SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    van Landeghem AA,Poortman J,Nabuurs M,Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985; 45: 29002906.
  • 2
    Silva MC,Rowlands MG,Dowsett M, et al. Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res. 1989; 49: 25882591.
  • 3
    Brodie A,Lu Q,Nakamura J. Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol. 1997; 61: 281286.
  • 4
    Yue W,Zhou DJ,Chen S,Brodie AMH. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 1994; 54: 50925095.
  • 5
    Brodie AH,Jelovac D,Long B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem Mol Biol. 2003; 86: 283288.
  • 6
    Macedo LF,Guo Z,Tilghman SL,Sabnis GJ,Qiu Y,Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006; 66: 77757782.
  • 7
    Sabnis G,Macedo L,Goloubeva O,Schayowitz A,Zhu Y,Brodie A. Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2007 Sep 7; [Epub ahead of print].
  • 8
    Macedo L,Sabnis G,Moreira TH, et al. Effects of combining the aromatase inhibitor anastrozole with fulvestrant in the intratumoral aromatase model. In: American Association for Cancer Research Annual Meeting Proceedings; Los Angeles, Calif, April 14–18. Philadelphia, Pa: AACR; 2007 Abstract 992. Available from URL: http://www.abstractsonline.com/viewer/searchresults.asp Accessed June 15, 2007.
  • 9
    Long BJ,Jelovac D,Thiantanawat A,Brodie AM. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res. 2002; 8: 23782388.
  • 10
    Long BJ,Jelovac D,Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in breast cancer model. J Natl Cancer Inst. 2004; 96: 456465.
  • 11
    Baum M,Buzdar AU,Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002; 59: 21312139.
  • 12
    Coombes RC,Hall E,Gibson LJ. A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092.
  • 13
    Jelovac D,Sabnis G,Long BJ,Goloubeva OG,Brodie AMH. Activation of MAPK in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 2005; 65: 53805389.
  • 14
    Kato S,Endoh H,Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270: 14911494.
  • 15
    Joel PB,Traish AM,Lannigan DA. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. JBiol Chem. 1998; 273: 1331713323.
  • 16
    Santen RJ,Song RX,McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002; 80: 239256.
  • 17
    Chen D,Washbrook E,Sarwar N. Phosphorylation of human estrogen receptor alpha at serine 118 by 2 distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene. 2002; 21: 49214931.
  • 18
    Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 2003; 17: 309317.
  • 19
    Sabnis G,Schayowitz A,Goloubeva O,Brodie A. Trastuzumab increases sensitivity of hormone dependent and hormone refractory breast cancer cells to endocrine agents. In: American Association of Cancer Research 100th Annual Meeting Proceedings. Los Angeles, CA, April 14–18, 2007. Abstract 991.
  • 20
    Konecny G,Pauletti G,Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003; 95: 142153.
  • 21
    Jelovac D,Macedo L,Goloubeva OG,Handratta V,Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 2005; 65: 54395444.
  • 22
    Nicholson RI,Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer. 2000; 82: 501513.
  • 23
    Yue W,Wang JP,Conaway M,Masamura S,Li S,Santen RJ. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology. 2002; 143: 32213229.
  • 24
    Sabnis GJ,Jelovac D,Long B,Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 2005; 65: 39033910.